IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection

Oncoimmunology. 2020 Jul 9;9(1):1790716. doi: 10.1080/2162402X.2020.1790716.

Abstract

IL15 is a key cytokine for the activation and survival of anti-tumor effectors CD8+ T and NK cells. Recently published preclinical studies demonstrate that the therapeutic activity of IL15 requires conventional dendritic cells type 1 (cDC1). Radiotherapy cooperates with IL15 by enhancing cDC1 tumor infiltration via interferon type 1 activation.

Keywords: CD8 T-cells; IL-15; dendritic cells; interferon type 1; radiotherapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • CD8-Positive T-Lymphocytes
  • Dendritic Cells
  • Humans
  • Interleukin-15*
  • Killer Cells, Natural
  • Neoplasms* / radiotherapy

Substances

  • IL15 protein, human
  • Interleukin-15